But the approval roll for the sphingosine 1-phosphate (S1P) receptor modulator may be over. Thursday, the New Jersey company said its trial assessing Zeposia in Crohn’s disease had come up short.
The company said an initial analysis of results from a 12-week induction study showed that the drug did not meet its primary endpoint of clinical remission at Week 12. BMS did not provide detailed data nor reveal its plan for Zeposia in the indication.
“To date, no S1P modulator has shown an effect in a phase 3 trial in Crohn’s disease, where a high unmet medical need remains for new therapies that offer more patients relief from symptoms and the potential for remission,” Roland Chen, M.D., BMS’ head of immunology, cardiovascular and neuroscience development, said in a release.
The trial enrolled 600 participants who did not have success with at least one prior treatment and is the first of two 12-week induction studies comparing Zeposia to placebo.
Also part of the YELLOWSTONE program is a 52-week maintenance study for those who responded to treatment and an optional, 264-week, open-label extension study open to non-responders, plus those with disease relapse during maintenance and those who completed the maintenance trial.
Zeposia was approved for relapsing MS in 2020. A year later came the UC nod, providing patients with a first-in-class alternatives to biologic treatments such as Johnson & Johnson’s Stelara, AbbVie’s Humira and Takeda’s Entyvio, which have dominated the indication. Zeposia is administered orally as opposed to the biologics, which are infused.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.